GWM
CLBT icon

Geneos Wealth Management’s Cellebrite CLBT Stock Holding History

Geneos Wealth Management’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-417
Closed -$6.67K – 2621
2025
Q2 		$6.67K Hold
417
– – ﹤0.01% 2478
2025
Q1 		$8.1K Buy
+417
New +$8.78K ﹤0.01% 2343

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return

Geneos Wealth Management's CLBT Position: Q3 2025 in Review

Geneos Wealth Management sold out of Cellebrite (CLBT) in Q3 2025, closing a stake of 417 shares — an estimated $6.67K sold.

Geneos Wealth Management first reported a position in CLBT in Q1 2025 and held it in 2 quarters. The position peaked at $8.1K in Q1 2025. 197 funds tracked by Wall St. Rank hold CLBT as of Q3 2025.

  • Geneos Wealth Management reported no remaining Cellebrite position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 417 Cellebrite shares in Q3 2025, an estimated $6.67K.
  • Geneos Wealth Management first reported a position in Cellebrite in Q1 2025 and held it in 2 quarters.
  • Geneos Wealth Management's Cellebrite position peaked at $8.1K in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Cellebrite as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.